|
|||||||
|
Fusion Protein:BCAN-NTRK1 |
Fusion Gene and Fusion Protein Summary |
 Fusion gene summary |
| Fusion partner gene information | Fusion gene name: BCAN-NTRK1 | FusionPDB ID: 9146 | FusionGDB2.0 ID: 9146 | Hgene | Tgene | Gene symbol | BCAN | NTRK1 | Gene ID | 63827 | 4914 |
| Gene name | brevican | neurotrophic receptor tyrosine kinase 1 | |
| Synonyms | BEHAB|CSPG7 | MTC|TRK|TRK1|TRKA|Trk-A|p140-TrkA | |
| Cytomap | 1q23.1 | 1q23.1 | |
| Type of gene | protein-coding | protein-coding | |
| Description | brevican core proteinbrain-enriched hyaluronan-binding proteinchondroitin sulfate proteoglycan 7chondroitin sulfate proteoglycan BEHAB | high affinity nerve growth factor receptorOncogene TRKTRK1-transforming tyrosine kinase proteingp140trkneurotrophic tyrosine kinase, receptor, type 1tropomyosin-related kinase Atyrosine kinase receptor A | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | Q96GW7 Main function of 5'-partner protein: FUNCTION: May play a role in the terminally differentiating and the adult nervous system during postnatal development. Could stabilize interactions between hyaluronan (HA) and brain proteoglycans. | P04629 Main function of 5'-partner protein: FUNCTION: Receptor tyrosine kinase involved in the development and the maturation of the central and peripheral nervous systems through regulation of proliferation, differentiation and survival of sympathetic and nervous neurons. High affinity receptor for NGF which is its primary ligand (PubMed:1850821, PubMed:1849459, PubMed:1281417, PubMed:8325889, PubMed:15488758, PubMed:22649032, PubMed:17196528, PubMed:27445338). Can also bind and be activated by NTF3/neurotrophin-3. However, NTF3 only supports axonal extension through NTRK1 but has no effect on neuron survival (By similarity). Upon dimeric NGF ligand-binding, undergoes homodimerization, autophosphorylation and activation (PubMed:1281417). Recruits, phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades driving cell survival and differentiation. Through SHC1 and FRS2 activates a GRB2-Ras-MAPK cascade that regulates cell differentiation and survival. Through PLCG1 controls NF-Kappa-B activation and the transcription of genes involved in cell survival. Through SHC1 and SH2B1 controls a Ras-PI3 kinase-AKT1 signaling cascade that is also regulating survival. In absence of ligand and activation, may promote cell death, making the survival of neurons dependent on trophic factors. {ECO:0000250|UniProtKB:P35739, ECO:0000250|UniProtKB:Q3UFB7, ECO:0000269|PubMed:11244088, ECO:0000269|PubMed:1281417, ECO:0000269|PubMed:15488758, ECO:0000269|PubMed:17196528, ECO:0000269|PubMed:1849459, ECO:0000269|PubMed:1850821, ECO:0000269|PubMed:22649032, ECO:0000269|PubMed:27445338, ECO:0000269|PubMed:27676246, ECO:0000269|PubMed:8155326, ECO:0000269|PubMed:8325889}.; FUNCTION: [Isoform TrkA-III]: Resistant to NGF, it constitutively activates AKT1 and NF-kappa-B and is unable to activate the Ras-MAPK signaling cascade. Antagonizes the anti-proliferative NGF-NTRK1 signaling that promotes neuronal precursors differentiation. Isoform TrkA-III promotes angiogenesis and has oncogenic activity when overexpressed. {ECO:0000269|PubMed:15488758}. | |
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000329117, ENST00000361588, | ENST00000531606, ENST00000358660, ENST00000368196, ENST00000392302, ENST00000524377, |
| Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 2 X 2 X 2=8 | 25 X 24 X 13=7800 |
| # samples | 3 | 33 | |
| ** MAII score | log2(3/8*10)=1.90689059560852 | log2(33/7800*10)=-4.56293619439116 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Fusion gene context | PubMed: BCAN [Title/Abstract] AND NTRK1 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Fusion neoantigen context | PubMed: BCAN [Title/Abstract] AND NTRK1 [Title/Abstract] AND neoantigen [Title/Abstract] | ||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | BCAN(156628525)-NTRK1(156844697), # samples:1 BCAN(156628525)-NTRK1(156844698), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | BCAN-NTRK1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. BCAN-NTRK1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. BCAN-NTRK1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. BCAN-NTRK1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | NTRK1 | GO:0006468 | protein phosphorylation | 15488758 |
| Tgene | NTRK1 | GO:0008285 | negative regulation of cell proliferation | 15488758 |
| Tgene | NTRK1 | GO:0010976 | positive regulation of neuron projection development | 15488758 |
| Tgene | NTRK1 | GO:0018108 | peptidyl-tyrosine phosphorylation | 2927393 |
| Tgene | NTRK1 | GO:0043547 | positive regulation of GTPase activity | 15488758 |
| Tgene | NTRK1 | GO:0046579 | positive regulation of Ras protein signal transduction | 15488758 |
| Tgene | NTRK1 | GO:0046777 | protein autophosphorylation | 15488758 |
| Tgene | NTRK1 | GO:0048011 | neurotrophin TRK receptor signaling pathway | 15488758 |
| Tgene | NTRK1 | GO:0051092 | positive regulation of NF-kappaB transcription factor activity | 15488758 |
| Tgene | NTRK1 | GO:0070374 | positive regulation of ERK1 and ERK2 cascade | 15488758 |
| Tgene | NTRK1 | GO:1904646 | cellular response to amyloid-beta | 11927634 |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr1:156628525/chr1:156844697) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here. |
| Fusion gene breakpoints across BCAN (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene breakpoints across NTRK1 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
Top |
Fusion Amino Acid Sequences |
| Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000329117 | BCAN | chr1 | 156628525 | + | ENST00000392302 | NTRK1 | chr1 | 156844697 | + | 4256 | 2964 | 336 | 4103 | 1255 |
| ENST00000329117 | BCAN | chr1 | 156628525 | + | ENST00000368196 | NTRK1 | chr1 | 156844697 | + | 4312 | 2964 | 336 | 4103 | 1255 |
| ENST00000329117 | BCAN | chr1 | 156628525 | + | ENST00000524377 | NTRK1 | chr1 | 156844697 | + | 4104 | 2964 | 336 | 4103 | 1255 |
| ENST00000329117 | BCAN | chr1 | 156628525 | + | ENST00000358660 | NTRK1 | chr1 | 156844697 | + | 4182 | 2964 | 336 | 4112 | 1258 |
| ENST00000329117 | BCAN | chr1 | 156628525 | + | ENST00000392302 | NTRK1 | chr1 | 156844698 | + | 4256 | 2964 | 336 | 4103 | 1255 |
| ENST00000329117 | BCAN | chr1 | 156628525 | + | ENST00000368196 | NTRK1 | chr1 | 156844698 | + | 4312 | 2964 | 336 | 4103 | 1255 |
| ENST00000329117 | BCAN | chr1 | 156628525 | + | ENST00000524377 | NTRK1 | chr1 | 156844698 | + | 4104 | 2964 | 336 | 4103 | 1255 |
| ENST00000329117 | BCAN | chr1 | 156628525 | + | ENST00000358660 | NTRK1 | chr1 | 156844698 | + | 4182 | 2964 | 336 | 4112 | 1258 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000329117 | ENST00000392302 | BCAN | chr1 | 156628525 | + | NTRK1 | chr1 | 156844697 | + | 0.003442176 | 0.9965578 |
| ENST00000329117 | ENST00000368196 | BCAN | chr1 | 156628525 | + | NTRK1 | chr1 | 156844697 | + | 0.00335373 | 0.9966462 |
| ENST00000329117 | ENST00000524377 | BCAN | chr1 | 156628525 | + | NTRK1 | chr1 | 156844697 | + | 0.003690349 | 0.9963096 |
| ENST00000329117 | ENST00000358660 | BCAN | chr1 | 156628525 | + | NTRK1 | chr1 | 156844697 | + | 0.004429381 | 0.9955706 |
| ENST00000329117 | ENST00000392302 | BCAN | chr1 | 156628525 | + | NTRK1 | chr1 | 156844698 | + | 0.003442176 | 0.9965578 |
| ENST00000329117 | ENST00000368196 | BCAN | chr1 | 156628525 | + | NTRK1 | chr1 | 156844698 | + | 0.00335373 | 0.9966462 |
| ENST00000329117 | ENST00000524377 | BCAN | chr1 | 156628525 | + | NTRK1 | chr1 | 156844698 | + | 0.003690349 | 0.9963096 |
| ENST00000329117 | ENST00000358660 | BCAN | chr1 | 156628525 | + | NTRK1 | chr1 | 156844698 | + | 0.004429381 | 0.9955706 |
| Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones. |
Get the fusion protein sequences from here. |
| Fusion protein sequence information is available in the fasta format. >FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP |
Top |
Fusion Protein Breakpoint Sequences for BCAN-NTRK1 |
| +/-13 AA sequence from the breakpoints of the fusion protein sequences. |
| Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Length(fusion protein) | BP in fusion protein | Peptide |
| BCAN | chr1 | 156628525 | NTRK1 | chr1 | 156844697 | 2964 | 457 | FSEEEGKALEEEEKYEDEEEKEEEEE |
| BCAN | chr1 | 156628525 | NTRK1 | chr1 | 156844698 | 2964 | 457 | FSEEEGKALEEEEKYEDEEEKEEEEE |
Top |
Potential FusionNeoAntigen Information of BCAN-NTRK1 in HLA I |
| Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific. |
| BCAN-NTRK1_156628525_156844697.msa |
| Potential FusionNeoAntigen Information * We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5) |
| Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA I | FusionNeoAntigen peptide | Binding score | Immunogenic score | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
| BCAN-NTRK1 | chr1 | 156628525 | chr1 | 156844697 | 2964 | HLA-B15:17 | KALEEEEKY | 0.9918 | 0.9204 | 6 | 15 |
| BCAN-NTRK1 | chr1 | 156628525 | chr1 | 156844697 | 2964 | HLA-B58:01 | KALEEEEKY | 0.9842 | 0.8638 | 6 | 15 |
| BCAN-NTRK1 | chr1 | 156628525 | chr1 | 156844697 | 2964 | HLA-B58:02 | KALEEEEKY | 0.9817 | 0.9456 | 6 | 15 |
| BCAN-NTRK1 | chr1 | 156628525 | chr1 | 156844697 | 2964 | HLA-B15:16 | KALEEEEKY | 0.955 | 0.7625 | 6 | 15 |
| BCAN-NTRK1 | chr1 | 156628525 | chr1 | 156844697 | 2964 | HLA-B35:08 | KALEEEEKY | 0.9545 | 0.9087 | 6 | 15 |
| BCAN-NTRK1 | chr1 | 156628525 | chr1 | 156844697 | 2964 | HLA-B35:01 | KALEEEEKY | 0.8847 | 0.9666 | 6 | 15 |
| BCAN-NTRK1 | chr1 | 156628525 | chr1 | 156844697 | 2964 | HLA-B15:05 | KALEEEEKY | 0.9458 | 0.9647 | 6 | 15 |
| BCAN-NTRK1 | chr1 | 156628525 | chr1 | 156844697 | 2964 | HLA-C15:04 | KALEEEEKY | 0.85 | 0.8902 | 6 | 15 |
| BCAN-NTRK1 | chr1 | 156628525 | chr1 | 156844697 | 2964 | HLA-B57:04 | KALEEEEKY | 0.9824 | 0.7832 | 6 | 15 |
| BCAN-NTRK1 | chr1 | 156628525 | chr1 | 156844697 | 2964 | HLA-B58:06 | KALEEEEKY | 0.9808 | 0.8162 | 6 | 15 |
| BCAN-NTRK1 | chr1 | 156628525 | chr1 | 156844697 | 2964 | HLA-B15:20 | KALEEEEKY | 0.948 | 0.9688 | 6 | 15 |
| BCAN-NTRK1 | chr1 | 156628525 | chr1 | 156844697 | 2964 | HLA-B35:28 | KALEEEEKY | 0.9381 | 0.9635 | 6 | 15 |
| BCAN-NTRK1 | chr1 | 156628525 | chr1 | 156844697 | 2964 | HLA-B35:20 | KALEEEEKY | 0.9041 | 0.9612 | 6 | 15 |
| BCAN-NTRK1 | chr1 | 156628525 | chr1 | 156844697 | 2964 | HLA-B35:77 | KALEEEEKY | 0.8847 | 0.9666 | 6 | 15 |
| BCAN-NTRK1 | chr1 | 156628525 | chr1 | 156844697 | 2964 | HLA-C03:02 | KALEEEEKY | 0.8691 | 0.9809 | 6 | 15 |
| BCAN-NTRK1 | chr1 | 156628525 | chr1 | 156844697 | 2964 | HLA-C15:09 | KALEEEEKY | 0.85 | 0.8902 | 6 | 15 |
| BCAN-NTRK1 | chr1 | 156628525 | chr1 | 156844697 | 2964 | HLA-B48:02 | KALEEEEKY | 0.5738 | 0.9596 | 6 | 15 |
Top |
Potential FusionNeoAntigen Information of BCAN-NTRK1 in HLA II |
| Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific. |
| BCAN-NTRK1_156628525_156844697.msa |
| Potential FusionNeoAntigen Information * We used NetMHCIIpan v4.1 (%rank<0.5). |
| Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA II | FusionNeoAntigen peptide | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
| BCAN-NTRK1 | chr1 | 156628525 | chr1 | 156844697 | 2964 | DRB1-0840 | GKALEEEEKYEDEEE | 5 | 20 |
| BCAN-NTRK1 | chr1 | 156628525 | chr1 | 156844697 | 2964 | DRB1-1381 | GKALEEEEKYEDEEE | 5 | 20 |
| BCAN-NTRK1 | chr1 | 156628525 | chr1 | 156844697 | 2964 | DRB1-1388 | GKALEEEEKYEDEEE | 5 | 20 |
| BCAN-NTRK1 | chr1 | 156628525 | chr1 | 156844697 | 2964 | DRB1-1389 | GKALEEEEKYEDEEE | 5 | 20 |
| BCAN-NTRK1 | chr1 | 156628525 | chr1 | 156844697 | 2964 | DRB1-1389 | EGKALEEEEKYEDEE | 4 | 19 |
| BCAN-NTRK1 | chr1 | 156628525 | chr1 | 156844697 | 2964 | DRB1-1394 | GKALEEEEKYEDEEE | 5 | 20 |
Top |
Fusion breakpoint peptide structures of BCAN-NTRK1 |
| 3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens * The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA. |
| File name | BPseq | Hgene | Tgene | Hchr | Hbp | Tchr | Tbp | AAlen |
| 4108 | KALEEEEKYEDEEE | BCAN | NTRK1 | chr1 | 156628525 | chr1 | 156844697 | 2964 |
Top |
Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of BCAN-NTRK1 |
| Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens * We used Glide to predict the interaction between HLAs and neoantigens. |
| HLA allele | PDB ID | File name | BPseq | Docking score | Glide score |
| HLA-B14:02 | 3BVN | 4108 | KALEEEEKYEDEEE | -7.9962 | -8.1096 |
| HLA-B14:02 | 3BVN | 4108 | KALEEEEKYEDEEE | -5.70842 | -6.74372 |
| HLA-B52:01 | 3W39 | 4108 | KALEEEEKYEDEEE | -6.83737 | -6.95077 |
| HLA-B52:01 | 3W39 | 4108 | KALEEEEKYEDEEE | -4.4836 | -5.5189 |
| HLA-A11:01 | 4UQ2 | 4108 | KALEEEEKYEDEEE | -10.0067 | -10.1201 |
| HLA-A11:01 | 4UQ2 | 4108 | KALEEEEKYEDEEE | -9.03915 | -10.0745 |
| HLA-A24:02 | 5HGA | 4108 | KALEEEEKYEDEEE | -6.56204 | -6.67544 |
| HLA-A24:02 | 5HGA | 4108 | KALEEEEKYEDEEE | -5.42271 | -6.45801 |
| HLA-B44:05 | 3DX8 | 4108 | KALEEEEKYEDEEE | -7.85648 | -8.89178 |
| HLA-B44:05 | 3DX8 | 4108 | KALEEEEKYEDEEE | -5.3978 | -5.5112 |
| HLA-A02:01 | 6TDR | 4108 | KALEEEEKYEDEEE | -3.37154 | -4.40684 |
Top |
Vaccine Design for the FusionNeoAntigens of BCAN-NTRK1 |
| mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is. |
| Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide sequence | FusionNeoAntigen RNA sequence |
| BCAN-NTRK1 | chr1 | 156628525 | chr1 | 156844697 | 6 | 15 | KALEEEEKY | TCCTGTGTGCCCAGAAGACCTGTCTCG |
| mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs. |
| Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide | FusionNEoAntigen RNA sequence |
| BCAN-NTRK1 | chr1 | 156628525 | chr1 | 156844697 | 4 | 19 | EGKALEEEEKYEDEE | CAGATCTCCTGTGTGCCCAGAAGACCTGTCTCGGTGGCTGTGGGC |
| BCAN-NTRK1 | chr1 | 156628525 | chr1 | 156844697 | 5 | 20 | GKALEEEEKYEDEEE | ATCTCCTGTGTGCCCAGAAGACCTGTCTCGGTGGCTGTGGGCCTG |
Top |
Information of the samples that have these potential fusion neoantigens of BCAN-NTRK1 |
| These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens. |
| Cancer type | Fusion gene | Hchr | Hbp | Henst | Tchr | Tbp | Tenst | Sample |
| GBM | BCAN-NTRK1 | chr1 | 156628525 | ENST00000329117 | chr1 | 156844697 | ENST00000358660 | TCGA-19-2619 |
Top |
Potential target of CAR-T therapy development for BCAN-NTRK1 |
| Predicted 3D structure. We used RoseTTAFold. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features * Minus value of BPloci means that the break point is located before the CDS. |
| - In-frame and retained 'Transmembrane'. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Tgene | NTRK1 | chr1:156628525 | chr1:156844697 | ENST00000368196 | 8 | 16 | 424_439 | 0 | 791.0 | Transmembrane | Helical | |
| Tgene | NTRK1 | chr1:156628525 | chr1:156844697 | ENST00000392302 | 9 | 17 | 424_439 | 0 | 761.0 | Transmembrane | Helical | |
| Tgene | NTRK1 | chr1:156628525 | chr1:156844697 | ENST00000524377 | 9 | 17 | 424_439 | 0 | 797.0 | Transmembrane | Helical | |
| Tgene | NTRK1 | chr1:156628525 | chr1:156844698 | ENST00000368196 | 8 | 16 | 424_439 | 0 | 791.0 | Transmembrane | Helical | |
| Tgene | NTRK1 | chr1:156628525 | chr1:156844698 | ENST00000392302 | 9 | 17 | 424_439 | 0 | 761.0 | Transmembrane | Helical | |
| Tgene | NTRK1 | chr1:156628525 | chr1:156844698 | ENST00000524377 | 9 | 17 | 424_439 | 0 | 797.0 | Transmembrane | Helical |
| Subcellular localization prediction of the transmembrane domain retained fusion proteins * We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image. |
| Hgene | Hchr | Hbp | Henst | Tgene | Tchr | Tbp | Tenst | DeepLoc result |
Top |
Related Drugs to BCAN-NTRK1 |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to BCAN-NTRK1 |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Tgene | NTRK1 | C0020074 | HSAN Type IV | 17 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
| Tgene | NTRK1 | C0238463 | Papillary thyroid carcinoma | 3 | ORPHANET |
| Tgene | NTRK1 | C0002768 | Congenital Pain Insensitivity | 1 | ORPHANET |
| Tgene | NTRK1 | C0005586 | Bipolar Disorder | 1 | CTD_human |
| Tgene | NTRK1 | C0005587 | Depression, Bipolar | 1 | CTD_human |
| Tgene | NTRK1 | C0017638 | Glioma | 1 | CTD_human |
| Tgene | NTRK1 | C0020075 | Hereditary Sensory Autonomic Neuropathy, Type 5 | 1 | CTD_human;ORPHANET |
| Tgene | NTRK1 | C0024713 | Manic Disorder | 1 | CTD_human |
| Tgene | NTRK1 | C0027796 | Neuralgia | 1 | CTD_human |
| Tgene | NTRK1 | C0027819 | Neuroblastoma | 1 | CTD_human |
| Tgene | NTRK1 | C0033958 | Psychosis, Brief Reactive | 1 | CTD_human |
| Tgene | NTRK1 | C0033975 | Psychotic Disorders | 1 | CTD_human |
| Tgene | NTRK1 | C0036337 | Schizoaffective Disorder | 1 | CTD_human |
| Tgene | NTRK1 | C0036341 | Schizophrenia | 1 | CTD_human |
| Tgene | NTRK1 | C0036358 | Schizophreniform Disorders | 1 | CTD_human |
| Tgene | NTRK1 | C0038870 | Neuralgia, Supraorbital | 1 | CTD_human |
| Tgene | NTRK1 | C0042656 | Neuralgia, Vidian | 1 | CTD_human |
| Tgene | NTRK1 | C0234247 | Neuralgia, Atypical | 1 | CTD_human |
| Tgene | NTRK1 | C0234249 | Neuralgia, Stump | 1 | CTD_human |
| Tgene | NTRK1 | C0259783 | mixed gliomas | 1 | CTD_human |
| Tgene | NTRK1 | C0273115 | Lung Injury | 1 | CTD_human |
| Tgene | NTRK1 | C0338831 | Manic | 1 | CTD_human |
| Tgene | NTRK1 | C0423711 | Neuralgia, Perineal | 1 | CTD_human |
| Tgene | NTRK1 | C0423712 | Neuralgia, Iliohypogastric Nerve | 1 | CTD_human |
| Tgene | NTRK1 | C0555198 | Malignant Glioma | 1 | CTD_human |
| Tgene | NTRK1 | C0598589 | Inherited neuropathies | 1 | GENOMICS_ENGLAND |
| Tgene | NTRK1 | C0751371 | Neuralgia, Ilioinguinal | 1 | CTD_human |
| Tgene | NTRK1 | C0751372 | Nerve Pain | 1 | CTD_human |
| Tgene | NTRK1 | C0751373 | Paroxysmal Nerve Pain | 1 | CTD_human |
| Tgene | NTRK1 | C0752347 | Lewy Body Disease | 1 | CTD_human |
| Tgene | NTRK1 | C1833921 | Familial medullary thyroid carcinoma | 1 | CTD_human;GENOMICS_ENGLAND;ORPHANET |
| Tgene | NTRK1 | C2350344 | Chronic Lung Injury | 1 | CTD_human |
Copyright 2023-PresentThe University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information
Campus Carry|Site Policies